期刊文献+

Randomized Double-Blind Clinical Comparison of Sodium Ibandronate and Pamidronate Disodium for Treatment of 141 Patients with Malignant Tumor Ostealgia

Randomized Double-Blind Clinical Comparison of Sodium Ibandronate and Pamidronate Disodium for Treatment of 141 Patients with Malignant Tumor Ostealgia
暂未订购
导出
摘要 OBJECTIVE To evaluate the therapeuticeffect and potential adverse ef- fects of sodium ibandronate(SI)in patients with malignant tumor ostealgia. METHODS Patients were randomly classified into two groups.Group A(SI)of 68 patients who received 4 mg SI i.v.,and 73 patients in Group B (pamidronate disodium[PD])who received 60 mg PD i.v.A randomized, double-blind method,with PD as a positive drug control,was used to assess changes in bone pain and adverse effects over a three-week period. RESULTS A total of 141 patients were enrol ed in the study,with 136 cases of appraisable efficacy.The effective rate was 72.3%(47/65)in Group A,and 63.4%(45/71)in Group B.There was no significant difference in ef- ficacy or adverse effects between the 2 groups. CONCLUSION The SI injection,with a pronounced effect,can relieve bone pain caused by osseous metastasis from a malignant tumor.The cura- tive and adverse effects were similar compared to PD. OBJECTIVE To evaluate the therapeuticeffect and potential adverse effects of sodium ibandronate(SI)in patients with malignant tumor ostealgia. METHODS Patients were randomly classified into two groups.Group A(SI)of 68 patients who received 4 mg SI i.v.,and 73 patients in Group B (pamidronate disodium[PD])who received 60 mg PD i.v.A randomized, double-blind method,with PD as a positive drug control,was used to assess changes in bone pain and adverse effects over a three-week period. RESULTS A total of 141 patients were enrol ed in the study,with 136 cases of appraisable efficacy.The effective rate was 72.3%(47/65)in Group A,and 63.4%(45/71)in Group B.There was no significant difference in efficacy or adverse effects between the 2 groups. CONCLUSION The SI injection,with a pronounced effect,can relieve bone pain caused by osseous metastasis from a malignant tumor.The curative and adverse effects were similar compared to PD.
出处 《Chinese Journal of Clinical Oncology》 CSCD 2007年第2期103-108,共6页 中国肿瘤临床(英文版)
关键词 osseous metastasis sodium ibandronate pamidronate-disodium bone pain. 恶性癌性骨痛 治疗 伊班膦酸钠 帕米膦酸二钠 随机双盲临床对照
  • 相关文献

参考文献10

  • 1Body JJ,Bartl R,Burckhardt P,et al.Current use ofbisphosphonates in oncology[].Journal of Clinical Oncology.1998
  • 2Denoyelle C,Hong L,Vannier JP,et al.New insightsinto the actions of bisphosphonate zoledronic acid inbreast cancer cells by dual Rho-A-dependent and in-dependent effects[].British Journal of Cancer.2003
  • 3Wood J,Bonjean K,Ruetz S,et al.Novel anti-angiogen-ic effects of the bisphosphonate compound zoledronicacid[].Journal of Pharmacology and Experimental Therapeutics.2002
  • 4Santini D,Vincenzi B,Avvisati G,et al.Pamidronateinduces modifications of circulating angiogeneticfactors in cancer patients[].Clinical Cancer Research.2002
  • 5Boissier S,Ferreras M,Peyruchaud O,et al.Bisphos-phonates inhibit breast and prostate carcinoma cellinvasion,an early event in the formation of bone me-tastases[].Cancer Research.2000
  • 6Russell GG,Rogers MJ.Bisphosphonates:From thelaboratory to the clinic and back again[].Bone.1999
  • 7McLean SA,Domeier RM,DeVore HK,et al.The feasi-bility of pain assessment in the prehospital setting[].Prehospital Emergency Care.2004
  • 8Hiraga T,Williams PJ,Mundy GR,et al.The Bisphos-phonates ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metasta-ses[].Cancer Research.2001
  • 9Dai GH,Jiao SC,Li F,et al.Clinical observation of iban-dronate sodium in treatment of 97 cases with pain ofthe metastatic tumor of bone[].Chinese Journal of Clinical Oncology and Rehabilitation.2004
  • 10Dooley M,Balfour JA.Ibandronate[].Drugs.1999

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部